Correspondence on: “Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?” by Kay et al

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kay DM, et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med. 2020 May 18; https://doi.org/10.1038/s41436-020-0824-3 [Epub ahead of print].

  2. 2.

    Kraszewski JN, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20:608–613.

    Article  Google Scholar 

  3. 3.

    Dangouloff T, Burghes A, Tizzano EF, Servais L, NBS SMA Study Group. 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020;30:93–103.

    Article  Google Scholar 

  4. 4.

    Kariyawasam DST, Russell JS, Wiley V, et al. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22:557–565.

    Article  Google Scholar 

  5. 5.

    Vill K, et al. One year of newborn screening for SMA—results of a German pilot project. J Neuromuscul Dis. 2019;6:503–515.

    Article  Google Scholar 

  6. 6.

    Boemer F, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord. 2019;29:343–349.

    Article  Google Scholar 

  7. 7.

    Chien YH, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124–129.e1.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Laurent Servais MD, PhD.

Ethics declarations

Disclosure

T.D. has given lectures sponsored by Biogen and Roche. L.S. has given lectures and has served as a consultant for Roche, Biogen, Avexis, and Cytokinetics. L.S. is the project leader of the NBS in Southern Belgium, funded by Avexis, Roche, and Biogen. The other authors declare no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dangouloff, T., Boemer, F., Caberg, J. et al. Correspondence on: “Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?” by Kay et al. Genet Med (2020). https://doi.org/10.1038/s41436-020-0887-1

Download citation